COURSE OVERVIEW
Colorectal cancer (CRC) is the most common gastrointestinal cancer in the United States. Among all sites CRC is the third most commonly diagnosed malignancy in both genders in North America. The treatment of colorectal cancer has become increasingly complex over recent years.
Chemotherapy is effective in prolonging survival and time to disease progression in patients with metastatic CRC. With the emergence of new
chemotherapy drugs and targeted agents, there has been great improvement in the prognosis of patients with metastatic colorectal cancer. These advances in the treatment of metastatic CRC in the last decade have led to the development of more convenient drugs (oral fluoropyrimidines) and more effective regimens (CPT-11 or oxaliplatin added to fluoropyrimidines).
LEARNING OBJECTIVES
After successfully completing this CME course, the participant should be able to:
• Treat patients with metastatic colorectal cancer with systemic drugs.
• Understand chemotherapy and targeted therapy.